 Johnson Johnsons NYSE: JNJ Janssen has won an arbitration against Genmab AS NASDAQ: GMAB on two matters related to their licensing pact for multiple myeloma drug Darzalex daratumumab. The first issue around daratumumab arose because Janssen announced a deal. 